Trial of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation in Esophageal Cancer
Status:
Terminated
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The overall study objective is to evaluate the dose limiting toxicities and the recommended
phase II dose of Panitumumab when combined with the standard of care treatment with
cisplatin, fluorouracil and radiation in patients with locally advanced esophageal cancer.
The investigators will also be assessing the ability of PET (Positron Emission Tomography)
imaging to predict the degree of pathologic response.
All patients will have a pre-study FDG (F-18 Fluorodeoxyglucose) PET scan and will receive
radiation therapy and chemotherapy over a 35 day period. 4-8 weeks post radiation and
chemotherapy patients will be restaged with a PET/CT scan. It is anticipated that
approximately 30 patients enrolled will undergo an esophagectomy which is considered standard
of care post radiation and chemotherapy. The surgery will allow us to compare this study
regimen to the historical standard of care (Cisplatin/fluorouracil chemotherapy with
radiation therapy).